Date: 2016-05-11
Type of information: Nomination
Compound:
Company: Opko Health (USA - Fl)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 11, 2016, OPKO Health announced the appointment of Douglass Laidlaw , PhD as Vice President of Medical Affairs to support the anticipated launch of Rayaldee®. Dr. Laidlaw has over 15 years of experience in leading strategic planning, development and execution of medical education initiatives for numerous pharmaceutical companies, including Relypsa, Keryx, Sanofi, Genzyme, Neurocine Biosciences, Serono and Organon. He has been involved in new product launches targeting patients with chronic kidney disease and has deep connections with key nephrology opinion leaders. Prior to joining OPKO , Dr. Laidlaw served as Relypsa's Executive Director, Medical Affairs, and Sanofi's National Director, Medical Science Liaisons, Medical Affairs.
Financial terms:
Latest news:
